PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.65%
Both companies show declining cash positions (-7.65% vs AVXL's -11.22%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.65%
Cash + STI yoy 0.5-0.75x AVXL's -11.22%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Other current assets growth < half of AVXL's -100.00%. David Dodd sees a leaner approach to short-term items.
-5.46%
0.5-0.75x AVXL's -9.04%. Martin Whitman might see risk if this hampers near-term financial flexibility.
13.35%
Higher PP&E (Net) Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Higher Other Non-Current Assets Growth compared to AVXL's zero value, indicating worse performance.
2.60%
Higher Total Non-Current Assets Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-5.18%
0.5-0.75x AVXL's -9.03%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
41.04%
Less than half of AVXL's -7.91%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.09%
Above 1.5x AVXL's 21.05%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.41%
Above 1.5x AVXL's 21.05%. Michael Burry sees a potential leverage warning sign.
4.74%
Above 1.5x AVXL's 1.37%. Michael Burry suspects heavy new equity expansion or dilution.
-3.50%
0.5-0.75x AVXL's -5.62%. Martin Whitman is wary of weaker retention or lower profitability.
-4.99%
Less than half of AVXL's 100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-23.90%
≥ 1.5x AVXL's -13.12%. David Dodd sees stronger capital base growth than competitor.
-5.18%
0.5-0.75x AVXL's -9.03%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.42%
Similar yoy changes to AVXL's 11.22%. Walter Schloss sees parallel net leverage strategies.